Prudential Financial
GLUE icon

Prudential Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

Prudential Financial’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$926K Buy
+56,280
New +$1.08M ﹤0.01% 1629
2025
Q4 		– Sell
-12,054
Closed -$89.3K – 2303
2025
Q3 		$89.3K Hold
12,054
– – ﹤0.01% 2288
2025
Q2 		$54.4K Buy
+12,054
New +$53.8K ﹤0.01% 2339
2022
Q1 		– Sell
-73,845
Closed -$1.51M – 2637
2021
Q4 		$1.51M Buy
+73,845
New +$1.55M ﹤0.01% 1678

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Prudential Financial's GLUE Position: Q1 2026 in Review

Prudential Financial opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 56,280 shares worth $926K. The stake represents ﹤0.01% of the portfolio and ranks #1629 among its holdings. This is a return to the name: Prudential Financial previously reported a position in GLUE as recently as Q3 2025.

Prudential Financial first reported a position in GLUE in Q4 2021 and has held it in 4 quarters since. The position peaked at $1.51M in Q4 2021. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Prudential Financial held 56,280 shares of Monte Rosa Therapeutics worth $926K as of Q1 2026.
  • Monte Rosa Therapeutics was a new Prudential Financial position in Q1 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1629 holding.
  • Prudential Financial first reported a position in Monte Rosa Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Prudential Financial's Monte Rosa Therapeutics position peaked at $1.51M in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.